找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Cancer Immunology; Bench to Bedside Imm Nima Rezaei Book 2021Latest edition Springer Nature Switzerland AG 2021 Cancer immunotherapy.Transl

[復制鏈接]
查看: 42672|回復: 68
樓主
發(fā)表于 2025-3-21 16:19:21 | 只看該作者 |倒序瀏覽 |閱讀模式
書目名稱Cancer Immunology
副標題Bench to Bedside Imm
編輯Nima Rezaei
視頻videohttp://file.papertrans.cn/222/221129/221129.mp4
概述Describes in detail novel strategies in cancer immunotherapy and targeting of tumor immunosuppression.Provides a bench to bedside approach to the immunology of cancers, with a focus on clinical aspect
圖書封面Titlebook: Cancer Immunology; Bench to Bedside Imm Nima Rezaei Book 2021Latest edition Springer Nature Switzerland AG 2021 Cancer immunotherapy.Transl
描述.This translational, clinically oriented book describes in detail novel approaches to cancer immunotherapy, current strategies to target tumor immunosuppression, and prognostic biomarkers for personalized cancer treatments. Since the first, very successful edition of the book was published in 2015, the original chapters have been significantly updated and entirely new chapters are included on, for example, cancer immunoprevention, aptamer-mediated cancer gene therapy, haploidentical bone marrow transplantation for pediatric malignancies, and nanoimmunotherapy. .The book is published as part of the three-volume Springer series .Cancer Immunology., which aims to provide an up-to-date, clinically relevant review of cancer immunology and immunotherapy. Other volumes in the series address the translational medicine context and cancer immunotherapy for organ-specific tumors. .Cancer Immunology: Bench to Bedside Immunotherapy of Cancers. .will be of special value to clinical immunologists, hematologists, and oncologists...?.
出版日期Book 2021Latest edition
關鍵詞Cancer immunotherapy; Translational medicine; Prognostic biomarkers; Tumor immunosuppression; Gene thera
版次2
doihttps://doi.org/10.1007/978-3-030-50287-4
isbn_softcover978-3-030-50289-8
isbn_ebook978-3-030-50287-4
copyrightSpringer Nature Switzerland AG 2021
The information of publication is updating

書目名稱Cancer Immunology影響因子(影響力)




書目名稱Cancer Immunology影響因子(影響力)學科排名




書目名稱Cancer Immunology網(wǎng)絡公開度




書目名稱Cancer Immunology網(wǎng)絡公開度學科排名




書目名稱Cancer Immunology被引頻次




書目名稱Cancer Immunology被引頻次學科排名




書目名稱Cancer Immunology年度引用




書目名稱Cancer Immunology年度引用學科排名




書目名稱Cancer Immunology讀者反饋




書目名稱Cancer Immunology讀者反饋學科排名




單選投票, 共有 1 人參與投票
 

0票 0.00%

Perfect with Aesthetics

 

0票 0.00%

Better Implies Difficulty

 

1票 100.00%

Good and Satisfactory

 

0票 0.00%

Adverse Performance

 

0票 0.00%

Disdainful Garbage

您所在的用戶組沒有投票權限
沙發(fā)
發(fā)表于 2025-3-21 20:34:36 | 只看該作者
Strategies to Target Tumor Immunosuppression,osuppression, are pivotal for potent antitumor immunity..This chapter provides an overview of the main immune tolerance and immunosuppression mechanisms within the tumor microenvironment and discusses effective immunotherapeutic interventions that target homing and activity of immune effector cells
板凳
發(fā)表于 2025-3-22 03:09:55 | 只看該作者
地板
發(fā)表于 2025-3-22 07:29:43 | 只看該作者
5#
發(fā)表于 2025-3-22 10:01:30 | 只看該作者
Combination of Chemotherapy and Cytokine Therapy in Treatment of Cancers,okines have demonstrated potential for therapeutic synergy. For example, it is possible to potentiate the development of specific immune response by reducing the dose of conventional chemotherapy (e.g., cyclophosphamide, gemcitabine, paclitaxel, and doxorubicin). This chapter provides currently evid
6#
發(fā)表于 2025-3-22 14:33:42 | 只看該作者
7#
發(fā)表于 2025-3-22 20:41:35 | 只看該作者
8#
發(fā)表于 2025-3-22 23:33:33 | 只看該作者
Adoptive T-Cell Therapy: Optimizing Chemokine Receptor-Mediated Homing of T-Cells in Cancer Immunotoited to improve T-cell homing to tumors. The possibility of developing novel strategies to bring more T-cell effectors into tumors will surely enhance the efficacy of adoptive T-cell therapies. These strategies, also in combination with current checkpoint blockade, hold great promise for the future
9#
發(fā)表于 2025-3-23 01:36:34 | 只看該作者
Toll-Like Receptor Pathway and Its Targeting in Treatment of Cancers,ancer progression. Hence, more investigations are required to discover proper therapeutic approaches for cancer. Multiple trials have been designed recently to detect the therapeutic role of TLR agonist in addition to chemotherapy. Also, the role of TLR agonist as a vaccine adjuvant for different ty
10#
發(fā)表于 2025-3-23 08:59:14 | 只看該作者
 關于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-25 03:46
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權所有 All rights reserved
快速回復 返回頂部 返回列表
晋中市| 师宗县| 怀安县| 库车县| 孟州市| 虞城县| 苍梧县| 苏州市| 灌阳县| 荔波县| 太保市| 尼勒克县| 陈巴尔虎旗| 景东| 武强县| 保靖县| 宁晋县| 郴州市| 新巴尔虎右旗| 裕民县| 潢川县| 石阡县| 巴彦淖尔市| 南安市| 镇宁| 嘉义县| 楚雄市| 乌鲁木齐县| 甘泉县| 宁海县| 平罗县| 牡丹江市| 赤壁市| 灌南县| 双桥区| 磴口县| 五台县| 信丰县| 开鲁县| 武清区| 平远县|